Trials are reportedly underway to find vaccines specially modified to tackle new variants and analyze the effects of a third injection as part of a cycle of inoculations.
The research would be overseen by Chris Whitty, England’s chief medical officer.
In the UK, three different vaccines are currently in use to protect against the coronavirus – Pfizer-BioNTech, Oxford-AstraZeneca and Moderna.
As part of the mass inoculation effort, nearly 35 million first doses of a Covid vaccine were administered, along with 15.6 million second doses administered.
Those over 40 are now being offered a shot as the program is deployed at high speed.
The Times reports that in new trials, those over 50 could receive a third jab course in the fall to boost their protection until the end of the year.
The document reports that the initial findings of the trials have “prompted the government to hope that both approaches will be able to negate any threats from new and existing variants.”
It is also said that the third shot would only go to this age group and those with underlying health conditions that may be at higher risk.
Apparently, one method of administering the booster would be at the same time as the annual influenza vaccine, but in the other arm.
A senior government minister reportedly said: “We will soon have a lot to say about the stimulus package. It seems really positive so far.
“We believe that the level of protection of the population against any variant will be so high that at Christmas, Covid-19 should have disappeared like any other disease in circulation.
“So much so that we don’t think it will be necessary to give a booster shot to young people because the transmission will be so low. “
This precedes a likely easing of restrictions from May 17, which will see the return of a series of freedoms.
Among the eased restrictions, pubs, cafes and restaurants will be able to accommodate guests indoors, while cinemas and attractions, including museums, will be able to reopen.
Some overseas trips should also open with more details on this in the coming days.